Insider Selling: Regeneron Pharmaceuticals, Inc. (REGN) Director Sells 2,000 Shares of Stock
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Charles A. Baker sold 2,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at $4,950,000. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 1.43% during trading on Tuesday, hitting $455.63. The company’s stock had a trading volume of 595,334 shares. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The stock has a market cap of $48.31 billion, a PE ratio of 45.71 and a beta of 1.63. The company has a 50-day moving average price of $461.31 and a 200-day moving average price of $450.61.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same period last year, the firm posted $2.82 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.93 EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in REGN. Intl Fcstone Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $346,000. Lord Abbett & CO. LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $51,931,000. Toronto Dominion Bank raised its position in shares of Regeneron Pharmaceuticals by 25.8% during the 2nd quarter. Toronto Dominion Bank now owns 25,835 shares of the biopharmaceutical company’s stock worth $12,686,000 after purchasing an additional 5,295 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $713,000. Finally, Public Employees Retirement System of Ohio raised its position in shares of Regeneron Pharmaceuticals by 1.6% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 54,288 shares of the biopharmaceutical company’s stock worth $26,663,000 after purchasing an additional 867 shares during the last quarter. Institutional investors and hedge funds own 67.95% of the company’s stock.
REGN has been the subject of several research reports. Leerink Swann reiterated an “outperform” rating and set a $573.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 22nd. Raymond James Financial, Inc. reissued an “outperform” rating and set a $547.00 price objective (up from $475.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. Bank of America Corporation reissued a “buy” rating and issued a $593.00 target price (up from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. BMO Capital Markets reissued a “market perform” rating and issued a $484.00 target price (up from $421.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Finally, Sanford C. Bernstein lowered Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $410.00 to $480.00 in a research note on Monday, June 26th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $487.26.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.